Affiliations: [a]
Department of Psychology & Center for Optimal Aging, Marymount University, Arlington, VA, USA
| [b]
Institute of Cognitive Science, University of Colorado, Boulder, CO, USA
| [c]
Department of Clinical Medicine, University of Tromsø-the Arctic University of Norway, Tromsø-, Norway
Correspondence:
[*]
Correspondence to: Catherine Diaz-Asper, Marymount University, 2807 N. Glebe Rd, Arlington, VA 22207, USA. E-mail: cdiazasp@marymount.edu.
Abstract: This study surveyed 51 specialist clinicians for their views on existing cognitive screening tests for mild cognitive impairment and their opinions about a hypothetical remote screener driven by artificial intelligence (AI). Responses revealed significant concerns regarding the sensitivity, specificity, and time taken to administer current tests, along with a general willingness to consider adopting telephone-based screening driven by AI. Findings highlight the need to design screeners that address the challenges of recognizing the earliest stages of cognitive decline and that prioritize not only accuracy but also stakeholder input.
Keywords: Alzheimer’s disease, artificial intelligence, attitude of health personnel, mental status and dementia test, mild cognitive impairment
